These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 17987649)

  • 1. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease.
    Sung YH; Chung SJ; Kim SR; Lee MC
    Mov Disord; 2008 Jan; 23(1):137-40. PubMed ID: 17987649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinically important difference on the unified Parkinson's disease rating scale.
    Shulman LM; Gruber-Baldini AL; Anderson KE; Fishman PS; Reich SG; Weiner WJ
    Arch Neurol; 2010 Jan; 67(1):64-70. PubMed ID: 20065131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
    Tarsy D; Scollins L; Corapi K; O'Herron S; Apetauerova D; Norregaard T
    Stereotact Funct Neurosurg; 2005; 83(5-6):222-7. PubMed ID: 16534254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of tremor and bradykinesia in Parkinson's disease using a novel ambulatory monitoring system.
    Salarian A; Russmann H; Wider C; Burkhard PR; Vingerhoets FJ; Aminian K
    IEEE Trans Biomed Eng; 2007 Feb; 54(2):313-22. PubMed ID: 17278588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the structure of motor symptoms of Parkinson's disease.
    Stochl J; Boomsma A; Ruzicka E; Brozova H; Blahus P
    Mov Disord; 2008 Jul; 23(9):1307-12. PubMed ID: 18464275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced Parkinson's disease by subthalamotomy: one-year results.
    Su PC; Tseng HM; Liu HM; Yen RF; Liou HH
    Mov Disord; 2003 May; 18(5):531-8. PubMed ID: 12722167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses.
    Louis ED; Levy G; Côte LJ; Mejia H; Fahn S; Marder K
    Mov Disord; 2002 May; 17(3):513-7. PubMed ID: 12112199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative measures of fine motor, limb, and postural bradykinesia in very early stage, untreated Parkinson's disease.
    Koop MM; Shivitz N; Brontë-Stewart H
    Mov Disord; 2008 Jul; 23(9):1262-8. PubMed ID: 18464283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of impairments and disabilities in Parkinson's disease.
    Visser M; Marinus J; Stiggelbout AM; van Hilten JJ
    Parkinsonism Relat Disord; 2006 Jun; 12(5):314-8. PubMed ID: 16621658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.